266 related articles for article (PubMed ID: 26453583)
1. Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Yokoyama S; Perera PY; Terawaki S; Watanabe N; Kaminuma O; Waldmann TA; Hiroi T; Perera LP
J Clin Immunol; 2015 Oct; 35(7):661-7. PubMed ID: 26453583
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Dowdell KC; Pesnicak L; Hoffmann V; Steadman K; Remaley AT; Cohen JI; Straus SE; Rao VK
Exp Hematol; 2009 Apr; 37(4):487-94. PubMed ID: 19217201
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.
Yokoyama S; Perera PY; Waldmann TA; Hiroi T; Perera LP
J Clin Immunol; 2013 Apr; 33(3):586-94. PubMed ID: 23269601
[TBL] [Abstract][Full Text] [Related]
4. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
5. Abnormal thymic maturation and lymphoproliferation in MRL-Fas
Ashman RF; Singh N; Lenert PS
Lupus; 2017 Jun; 26(7):734-745. PubMed ID: 27837196
[TBL] [Abstract][Full Text] [Related]
6. Stabilized
Xu X; Huang J; Zhao M; Chen H; Mo J; Zhou X; Su Q; Yu B; Huang Z
J Immunol Res; 2017; 2017():3469108. PubMed ID: 29250557
[TBL] [Abstract][Full Text] [Related]
7. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune Lymphoproliferative Syndrome-FAS Patients Have an Abnormal Regulatory T Cell (Treg) Phenotype but Display Normal Natural Treg-Suppressive Function on T Cell Proliferation.
Mazerolles F; Stolzenberg MC; Pelle O; Picard C; Neven B; Fischer A; Magerus-Chatinet A; Rieux-Laucat F
Front Immunol; 2018; 9():718. PubMed ID: 29686686
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
11. IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes.
Boggio E; Clemente N; Mondino A; Cappellano G; Orilieri E; Gigliotti CL; Toth E; Ramenghi U; Dianzani U; Chiocchetti A
Blood; 2014 Feb; 123(8):1178-86. PubMed ID: 24363402
[TBL] [Abstract][Full Text] [Related]
12. Next Generation Sequencing for Detecting Somatic
López-Nevado M; Docampo-Cordeiro J; Ramos JT; Rodríguez-Pena R; Gil-López C; Sánchez-Ramón S; Gil-Herrera J; Díaz-Madroñero MJ; Delgado-Martín MA; Morales-Pérez P; Paz-Artal E; Magerus A; Rieux-Laucat F; Allende LM
Front Immunol; 2021; 12():656356. PubMed ID: 33995372
[TBL] [Abstract][Full Text] [Related]
13. TCF1 deficiency ameliorates autoimmune lymphoproliferative syndrome (ALPS)-like phenotypes of lpr/lpr mice.
Xu X; Yu B; Cai W; Huang Z
Scand J Immunol; 2017 Jun; 85(6):406-416. PubMed ID: 28349581
[TBL] [Abstract][Full Text] [Related]
14. Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity.
Stevenson W; Sadrai Z; Hua J; Kodati S; Huang JF; Chauhan SK; Dana R
Cornea; 2014 Feb; 33(2):177-83. PubMed ID: 24342887
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
16. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
[TBL] [Abstract][Full Text] [Related]
17. A composite picture of TcR alpha/beta(+) CD4(-)CD8(-) T Cells (alpha/beta-DNTCs) in humans with autoimmune lymphoproliferative syndrome.
Bleesing JJ; Brown MR; Novicio C; Guarraia D; Dale JK; Straus SE; Fleisher TA
Clin Immunol; 2002 Jul; 104(1):21-30. PubMed ID: 12139944
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
19. Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency.
Rensing-Ehl A; Völkl S; Speckmann C; Lorenz MR; Ritter J; Janda A; Abinun M; Pircher H; Bengsch B; Thimme R; Fuchs I; Ammann S; Allgäuer A; Kentouche K; Cant A; Hambleton S; Bettoni da Cunha C; Huetker S; Kühnle I; Pekrun A; Seidel MG; Hummel M; Mackensen A; Schwarz K; Ehl S
Blood; 2014 Aug; 124(6):851-60. PubMed ID: 24894771
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction.
Meephansan J; Thummakriengkrai J; Ponnikorn S; Yingmema W; Deenonpoe R; Suchonwanit P
Arch Dermatol Res; 2017 Nov; 309(9):729-738. PubMed ID: 28884378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
